Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease.
about
Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorderCognitive dysfunction and depression in Parkinson's disease: what can be learned from rodent models?The mood-stabilizer lithium prevents hippocampal apoptosis and improves spatial memory in experimental meningitis.Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factors.Effects of treadmill exercise on hippocampal neurogenesis in an MPTP /probenecid-induced Parkinson's disease mouse modelAltered Wnt Signaling Pathway in Cognitive Impairment Caused by Chronic Intermittent Hypoxia: Focus on Glycogen Synthase Kinase-3β and β-catenin.Six psychotropics for pre-symptomatic & early Alzheimer's (MCI), Parkinson's, and Huntington's disease modification.Wnt and lithium: a common destiny in the therapy of nervous system pathologies?Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments.Targeting histone deacetylases: a novel approach in Parkinson's disease.Effects of lithium and valproic acid on BDNF protein and gene expression in an in vitro human neuron-like model of degeneration.Atorvastatin Prevents Early Oxidative Events and Modulates Inflammatory Mediators in the Striatum Following Intranasal 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Administration in Rats.Long-lasting recognition memory impairment and alterations in brain levels of cytokines and BDNF induced by maternal deprivation: effects of valproic acid and topiramate.Chronic Lithium Treatment in a Rat Model of Basal Forebrain Cholinergic Depletion: Effects on Memory Impairment and Neurodegeneration.Improved neuroprotective effects of resveratrol-loaded polysorbate 80-coated poly(lactide) nanoparticles in MPTP-induced Parkinsonism.Parkin-knockout mice did not display increased vulnerability to intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
P2860
Q24626017-01EC69D5-81B5-4C8C-BE92-9456164183F6Q34307633-3E86080A-8C42-4602-93D5-6ED5A17F78E1Q34542607-4B2CF909-B17B-4CEC-9914-494D45D30A21Q35978159-70B0EB9A-AE5C-4A0B-AF37-9BA6C22B35BEQ36342695-05B6C32D-DC68-41B2-BD5D-7BAE5AEEEC02Q36760994-EADD6EA7-C30D-4753-9766-7E991DDC4FDAQ37548320-A87257FF-600A-4041-8D06-C39B44FEF158Q38113139-DEEC4129-9B6A-441C-8BCC-16201736D433Q38126701-56E3B99B-68BA-4021-B84F-42D0B4D282B3Q38361065-0C8857CE-1EF1-4F09-80CC-8A82D952A2BEQ39008341-BC49C5E3-AA4A-45AD-BE9D-50AD45E5E417Q46256354-CA4B7325-ADA5-4F59-AD10-075C668164E4Q47732984-E10A231E-3C7D-432E-ABA6-D5A4DA066DF7Q47981799-1B9CAF07-B398-43FD-B68C-9ECC86045E9AQ48200129-CBF8A9F9-1179-40D4-8989-4623E49A07B1Q51066799-58743F73-91E6-4DCF-9B47-0F5BE46A15EE
P2860
Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Lithium and valproate prevent ...... model of Parkinson's disease.
@en
Lithium and valproate prevent ...... model of Parkinson's disease.
@nl
type
label
Lithium and valproate prevent ...... model of Parkinson's disease.
@en
Lithium and valproate prevent ...... model of Parkinson's disease.
@nl
prefLabel
Lithium and valproate prevent ...... model of Parkinson's disease.
@en
Lithium and valproate prevent ...... model of Parkinson's disease.
@nl
P50
P1476
Lithium and valproate prevent ...... t model of Parkinson's disease
@en
P2093
Adalberto A Castro
Karina Ghisoni
P304
P356
10.1016/J.BBR.2012.01.016
P407
P577
2012-01-17T00:00:00Z